Latest Thalidomide Stories
Trial conducted pursuant to Special Protocol Assessment with the Food and Drug Administration QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, Dec. 16 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
Carfilzomib induces a response in 45 percent of patients and reduces neuropathy.
Response Rate Increases to 41% and Median Overall Survival Reported at 25 Months for All Evaluable Patients QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.
NEW YORK, Dec.
'Renaissance' in use may lead to new treatments for controversial drug.
A British man Sunday said he will protest the government's refusal to compensate victims of the drug Thalidomide, administered to their mothers while pregnant.
- A serpent whose bite was fabled to produce intense thirst.